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Telomere signaling and metabolic dysfunction are hallmarks of cell aging. New agents targeting these processes
might provide therapeutic opportunities, including chemoprevention strategies against cancer predisposition. We
report identification and characterization of a pyrazolopyrimidine compound series identified from screens focused
on cell immortality and whose targets are glycolytic kinase PGK1 and oxidative stress sensor DJ1. We performed
structure–activity studies on the series to develop a photoaffinity probe to deconvolute the cellular targets. In vitro
binding and structural analyses confirmed these targets, suggesting that PGK1/DJ1 interact, which we confirmed
by immunoprecipitation. Glucose homeostasis and oxidative stress are linked to telomere signaling and exemplar
compound CRT0063465 blocked hypoglycemic telomere shortening. Intriguingly, PGK1 and DJ1 bind to TRF2 and
telomeric DNA. Compound treatment modulates these interactions and also affects Shelterin complex
composition, while conferring cellular protection from cytotoxicity due to bleomycin and desferroxamine. These
results demonstrate therapeutic potential of the compound series.
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Telomere attrition, genomic instability and cellular senescence are
hallmarks of aging [1]. Mammalian telomeres are nucleoprotein
structures comprising repeats of the sequence TTAGGG, bound by
sequence-specific and other factors which form a highly specialized
chromatin environment [2]. In normal somatic cells the end
replication problem, oxidative stress, and processing by nucleases
cause progressive telomere shortening during each round of cell
division, ultimately compromising protection at critically shortened
telomeres causing DNA damage signaling and senescence [3].
The shelterin complex, comprising TRF1, TRF2, POT1, TIN2,
TPP1, and RAP1, is the fundamental controller of telomere
protection and its composition and activities have been extensively
reviewed [4]. Shelterin proteins play diverse roles in length regulation,
telomerase recruitment, and suppression of DNA damage responses
and inappropriate repair. However, in aged normal cells with criticallyshortened telomeres these protective functions of shelterin are
abrogated. Telomere dysfunction also results from polymorphism
or mutation of telomerase or shelterin components. These variants
associate with cancer susceptibility, idiopathic pulmonary fibrosis,
and several accelerated aging syndromes, most notably dyskeratosis
congenita [5–10]. Restoring telomere protection is therefore an
important goal in aging research and cancer prevention.
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also powerful drivers of cell aging. Mitochondrial dysfunction and
anabolic signaling/ loss of nutrient sensing accelerate cell aging, while
dietary restriction increases organismal longevity and decreases
age-related pathologies in a variety of models [1]. These observations
have led to the suggestion that development of pharmacological
mimetics of caloric restriction is a promising avenue for anti-aging
drug discovery [11]. Among these agents, glycolysis inhibitor
2-deoxyglucose (2-DG) attracted early attention and was shown to
increase longevity in nematodes. In rats, 2-DG produced caloric
restriction-like effects including decreased serum insulin and body
temperature in a rat study. Although 2-DG proved relatively toxic,
glycolysis remains an interesting target for development of these
agents [12].
One mechanism for promotion of aging by glycolysis involves
production of advanced glycosylation end products via glycation
reactions with glycolytic intermediate species including methyl-
glyoxal. In turn, glycation damage to DNA, lipids and proteins can
cause mitochondrial dysfunction, accelerating oxidative stress [13].
Recently, however, several studies have also emerged linking
glycolysis and mitochondrial function with telomere homeostasis
pathways. Glucose restriction has been shown to decrease hTERT
expression and telomerase activity [14]. Extra-nuclear hTERT has
also been reported to influence glucose uptake by interacting with
glucose transporters [15].
We have previously applied cell based- and virtual-screening
approaches for target and compound identification to selectively
modulate telomere signaling pathways [16–19]. We now report
characterization of CRT0063465, a novel pyrazolopyrimidine
compound that emerged from cell-based screens of telomere
signaling. CRT0063465 targets the nucleotide binding site of
glycolytic enzyme phosphoglycerate kinase 1 (PGK1). The com-
pound also appears to bind the multifunctional cytoprotective
glyoxalase protein PARK7/DJ1. We show here that DJ1 and PGK1
form a previously unknown complex in cells.
In further investigating cellular activity of CRT0063465, we found
it acts to block telomere erosion under hypoglycemic stress
independently of telomerase activity. These results prompted us to
investigate potential interactions of PGK1/DJ1 with telomeres. We
show that both proteins bind TRF2 and telomeric DNA. These
interactions are modulated by hypoglycemia and CRT0063465
treatment. Intriguingly, multiple other glycolytic enzymes also
associate with TRF2. In unstressed conditions, proteomic analysis
indicated that CRT0063465 causes shelterin remodeling through
recruitment of TPP1, TIN2 and exonuclease Apollo to TRF2.
Together, these results suggest that telomere signaling and energy
metabolism may be more tightly connected than previously supposed.
Beyond effects on telomere length, CRT0063465 also confers partial
resistance to several DNA damaging treatments, suggesting future
strategies for evaluation of its therapeutic potential.
Materials and Methods
Cells and Compounds
Cells were A2780 ovarian adenocarcinoma cells and HCT116
colorectal cancer cells. Before synthesis of CRT0105481, structure–
activity studies indicated C4-carboxylate (CRT0063465) and ester
moieties (CRT0063459) were optimal. Small substituents on the
CRT0063465 C2-aryl ring para-position (CRT0063465,CRT0063466) were better tolerated than larger substituents
(CRT0163463). Other ring substitution positions were poorly
tolerated (CRT0098928). These studies are detailed in PubChem
AID1259345. Un-labeled phenylazide derivative (CRT0066127)
was tested before synthesis of tritiated version CRT0105481.
Synthetic Routes
Syntheses are outlined schematically in Figure 1, below. Detailed
information and synthesis data for each step is provided in
Supplementary File 1.
Photoaffinity Cross-Linking and Autoradiography
Cells were incubated for 30 minutes in 10 nM or 100 nM
CRT0105481 then exposed to 120 mJ 254 nm UV light using a
Stratalinker (Agilent, Santa Clara, CA) and harvested for 2D gel
analysis and autoradiography. Gels were stained with Simply Blue
Safe Stain (Thermo Fisher Scientific, York, UK), infused with
En3hance autoradiography enhancer reagent (Perkin Elmer, War-
rington, UK), dried, and incubated with radiographic film for 1 week
(100 nM CRT0105481 gels) or 1 month (10 nM CRT0105481 gels)
at −70 °C. Labeled spots were excised for LC–MS/MS analysis.
Recombinant human proteins PGK1 (ab211320) and DJ1
(ab51198) for in vitro labelling were obtained from Abcam
(Cambridge, UK).
Two-Dimensional Electrophoresis
First dimension isoelectric focusing used an IPGphor (Amersham
Biosciences, UK) with surface temperature 20 °C and maximum
current 50 μA/strip. Proteins (500 μg) were precipitated with cold
acetone (1:4, overnight at −20 °C) and resuspended to final volume
350 μl with rehydration solution containing 8 M urea, 2%
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS), 10 mM 1,4-dithioerythritol (DTE), 2% resolytes pH
3–10, trace bromophenol blue (BB). Samples were applied to the
IPG-strip (24 cm pH 3–10 nonlinear; Amersham Biosciences, UK)
by both passive (1 hr. @ 20 °C) and active rehydration (overnight, 50
V @ 20 °C). Focusing parameters were: step 1 – step hold 500 V for 1
h; step 2 – gradient 1000 V for 1 h; step 3 – gradient 8000 V for 3 h,
step 4 – hold 8000 V for approx. 63 kV h. Focused proteins were
reduced and alkylated during the equilibration step immediately
before transfer to the second dimension. IPG strips were first covered
with equilibration solution (50 mM Tris–HCl buffer (pH 8.8), 6 M
urea, 30% w/v glycerol, 2% w/v SDS, and a trace of BB) containing
(1% w/v) DTE for 15 min. This solution was replaced with
equilibration solution containing (4% w/v) iodoacetamide for 15
min. Equilibrated strips were separated across 5–20% gradient
SDS-PAGE gels (256 mm L × 200 mm W, (optigel,sigma)), using a
Ettan DALTtwelve system and standard SDS buffer (Invitrogen).
Gels were run at a 500 V (limits 350 A / 17 W per gel) until the dye
front left the gel (approximately 8 h).
2D Protein Spots LC–MS Analysis
Excised protein spots were washed by sequential dehydration/
hydration steps alternating between acetronitrile (MeCN) and 50
mM ammonium bicarbonate (AB). Trypsin digests were performed at
37 °C for 90 min followed by extraction (0.1% trifluoroacetic acid
and 5% MeCN), and concentration. Separation was performed on
Ultimate 3000 nanoLC (Dionex, Thermo Fisher Scientific, York,
UK). Samples were pre-concentrated on a PepMap100 trap column
Figure 1. Schema for synthesis of CRT0063465, CRT0066127, and tritiated photoaffinity cross-linking derivative CRT0105481.
Experimental details are given in Supplementary File 1.
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C18 analytical column using a gradient of 80% MeCN, 0.1% formic
acid; 8–25% for 70 minutes, then 25–50% for 30 minutes at 300 nl/
min. Samples were injected into a Q-Star mass spectrometer (Applied
Biosystems). MS data were acquired by 1.5-s survey scan (mass range
400–1200 Da) and data-dependent MS/MS of the three most intense
ions with charge state +2 to +4, for 2 s. These were then excluded
from acquisition for 30 s. Mass spectra recalibration used an in-house
script, searched against UniProtKB-Swiss-Prot (Ver. 54.3) using
Mascot 2.0 (Matrix Science) with mass tolerance of 12–30 ppm for
parent and 0.12 Da for fragments ions. The protein identification list
was filtered using non-MUDPit scoring.
TRF2 Pull-Down LC–MS Analysis
Gel lanes were excised to six approximately equal sized bands and
destained by successive washing (10 min, 30 °C) in water, 50%
acetonitrile, 0.1 M triethylammonium bicarbonate (TEAB, pH 8.5)and 50 mM TEAB in 50% acetonitrile. Gel was dehydrated in 100%
acetonitrile and dried by Speedvac (Thermo Fisher Scientific, York,
UK) before rehydration in 25 mM TEAB containing 5 μg/ml trypsin
overnight (30 °C). Digests were extracted sequentially with one
volume of 100% acetonitrile (15 min, 30 °C) and one volume of 25%
acetonitrile and 1.25% formic acid (15 min, 30 °C). Supernatants
were pooled and evaporated. Dried peptides were re-dissolved in 5%
acetonitrile/0.25% formic acid. Reversed-phase LC–MS/MS analysis
was performed on LTQ-Orbitrap Velos coupled to a Proxeon
Easy-LC (Thermo Fisher Scientific, York, UK). Peptide mixtures
were loaded onto C18 guard columns (1.9 μm; 0.1 × 20 mm) and
separated on a C18 in-house packed emitter (1.9 μm; 0.075 × 150
mm) over a 55 min linear gradient (5% to 45% B. A: 2% acetonitrile
0.1% formic acid B: 80% acetonitrile 0.1% formic acid). The
Orbitrap survey scan analysis (m/z 350 to 1600) was at 60,000
resolution and the top 10 ions in each duty cycle were selected for
MS/MS in the LTQ linear ion trap with collision-induced
Table 1. Crystallography data collection and refinement statistics. Values in parenthesis are for the
highest resolution shell
Data collection Refinement
Space group P21 Resolution (Å) 28.00-1.90
Cell parameters
a, b, c (Å); β (°)
35.9, 103.9, 50.7; 99.1 No. reflections 26,787
Resolution (Å) 30.0–1.9 (2.0–1.9) Rwork/Rfree 0.168/0.222
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was searched against Homo sapiens Swiss-Prot (148,212 entries) using
Mascot (2.4.1). Mascot files were loaded into Scaffold (4.3.4). The
mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium [20] via the PRIDE [21] partner
repository with the dataset identifier PXD011356 and https://doi.
org/10.6019/PXD011356.Rmeas 0.076 (0.387) No. atoms
(protein/ligand/water)
2977/23/234
bI/σIN 18.5 (5.9) B factors
(protein/ligand/water)
25/41/32
Completeness (%) 98.1 (96.7) R.M.S. deviations
Redundancy 6.7 (6.5) Bond length (Å)
Bond angle (°)
0.019
1.97Crystallography
Crystals of PGK1 in complex with 3-phosphoglycerate and MgCl2
were grown as previously described [22]. A single crystal was soaked
in 5 mM CRT0063465 for 3 days and flash-frozen in liquid nitrogen
using LV cryo-oil (MiTeGen) as cryoprotectant. Data collected to 1.9
Å resolution at 100 K on beamline I-04 at the Diamond synchrotron
(Harwell, UK) were processed using iMosflm [23] and CCP4 suite
[24]. The structure was solved using PHASER [25] and PGK1/
D-ATP as the search model (PDB 2ZGV). The model was rebuilt
using COOT [26] and refined using REFMAC5 [27]. Table 1
presents data collection and refinement statistics. The PGK1/
CRT0063465 structure is deposited in PDB (accession code 5NP8).In Silico Structural Modeling
Monomeric DJ1/PGK1 complex structure was derived by
overlaying the CRT0063465-PGK1 costructure with the
C106-sulfinic acid-bound DJ1 structure, and with PDB DJ1
structure (1P5F.PDB), aligning protein units through overlay of
bound CRT0063465 (CRT0063465 fragment in the case of the DJ1
structure). The resulting complex, containing only bound
CRT0063465 from the PGK1 crystal structure, showed protein–
protein steric clashes, so the DJ1 structure was subjected to local
energy minimization in loop regions contacting PGK1. The full
complex underwent constrained energy minimization, keeping the
ligand structure rigid. To construct the DJ1 dimeric complex, two
units of the minimized monomeric complex were overlain with the
dimer DJ1 crystal structure 1SOA.PDB, using DJ1 sequence.
Structural alignment guided positioning of protein units. Constrained
minimization was conducted on the final dimeric complex, again
keeping both ligand structures fixed. Calculations were performed
using Molecular Operating Environment (MOE) 2010.10 from
Chemical Computing Group Inc., using the Amber99 forcefield.
Surface Plasmon Resonance
SPR was performed using a ProteOn™ XPR36 system (BioRad,
Hemel Hempsted, UK). N 4000 RU of his-tagged PGK1 at
concentrations of 80 μg/ml and 25 μg/ml was immobilized by
amine coupling onto a GLH sensor chip. Subsequently,
CRT0063465 was injected over the chip in a range of concentrations
to determine Kd values. Purified recombinant PGK1 was obtained
from Crelux (Martinsried, Germany).
Immunoprecipitation
Immunoprecipitations were performed using Dynabeads (Thermo
Fisher Scientific, York, UK). Antibodies (10 μg) were coupled to M270
beads according to themanufacturer's protocol. Beads were washed in C1
buffer then C1-diluted antibodies added. Buffer C2 was added and
reactions incubated for 18 h at 37 °C.HB and SBwashes contained 0.1%
Tween-20 (Sigma-Aldrich, Dorset, UK). Before use, beads were washedin PBS containing 0.1% BSA. Lysates were prepared in kit extraction
buffer supplemented with EDTA-free protease inhibitor cocktail tablets
(Roche Diagnostics Ltd., West Sussex, UK) and 100 mM NaCl.
Immunoprecipitationswere performed for 30minutes at 4 °C, then beads
were washed and eluted. Antibodies were ab90787, PGK1; ab18257,
DJ1; and ab13579, TRF2 (Abcam, Cambridge, UK). Experiments were
performed twice.Western Blotting
Cytoplasmic and nuclear extracts were prepared with NE-PER
extraction reagents (Thermo Fisher Scientific, York, UK). Whole cell
extracts were prepared with Dynabeads lysis buffer (Thermo Fisher
Scientific, York, UK). Proteins were separated by SDS-PAGE, blotted
onto PVDF filter (Millipore, Watford, UK) and blocked overnight in
PBS-T containing 5% non-fat dried milk. Antibodies were ab67335,
PGK1; ab131591, DJ1; ab4182, TRF2; and ab97433, Ku80
(Abcam, Cambridge, UK). HRP-conjugated secondary was detected
using ECL HRP detection reagents (Amersham Pharmacia, Buck-
inghamshire, UK). Experiments were performed at least twice.Telomerase Activity Assays
TRAPeze XL kits were used for TRAP assay (Millipore, Watford,
UK). Cells were lysed in CHAPS buffer and protein concentrations
estimated by Bio-Rad assay (BioRad Laboratories Ltd., Hemel
Hempstead, UK). Protein (0.5 μg) was mixed with TRAPeze reaction
mix containing TS primer, fluorescein labeled RP primer, control
template and sulforhodamine labeled control K2 primer. Controls
included no-telomerase, no-Taq, and heat-treatment. 30 °C extension
products were detected by Q-PCR in triplicate using Chromo4
equipment (BioRad Laboratories Ltd., Hemel Hempstead, UK).
Total product was measured against TR8 standards. Experiments
were performed three times in triplicate.Telomere Restriction Fragment Analysis
Telomere length assays were performed using the teloTAGGG kit
(Roche Diagnostics Ltd., West Sussex, UK). One microgram of
genomic DNA was digested with HinfI/RsaI. Digests were separated
by gel electrophoresis and blotted onto positively charged membrane
(Roche Diagnostics Ltd., West Sussex, UK). Membranes were UV
cross-linked, baked at 120 °C and washed in 2×SSC solution.
Hybridization of DIG-labeled telomeric probe was performed using
buffers and probe provided. Membranes were washed, probed with
alkaline phosphatase-conjugated anti-DIG and exposed to CDP-star.
Experiments were performed twice.
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Cells cultured for 1 week in the presence of physiological glucose or
hypoglycemia and 10 nM CRT0063465 were harvested at 70%–80%
confluence, fixed in formaldehyde and lysed in SDS buffer with protease
inhibitors. Chromatin fragments (500 bp-1 kb) were generated by
sonication using a Branson S25OD sonifier (Branson Ultrasonics
Corp., Danbury, CT). Antibodies were Ab13579, TRF2; Ab67355,
PGK1; Ab131591, DJ1 (Abcam, Cambridge, UK). Each assay
included no-antibody control. Telomeric DNA was detected by
Q-PCR in triplicate using sybr green and Chromo4 equipment
(BioRad Laboratories Ltd., Hemel Hempstead, UK). Primers were
5′-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGG-
GTT-3′ and 5′-GGCTTGCCTTACCCTTACCCTTACCCT
TACCCTTACCCT-3′. Experiments were performed three times
with qPCR in triplicate on each occasion.
Electromobility Shift Assays
5-mer telomere oligonucleotide 5′-(TTAGGG)5-3′ (Sigma-Al-
drich, Dorset, UK) was 3′-biotinylated using Pierce reagents (Thermo
Fisher Scientific, York, UK) and hybridized to complementary
sequence oligonucleotide. Nuclear extracts were prepared using
NE-PER reagents (Thermo Fisher Scientific, York, UK). EMSAs
were performed using LightShift Chemiluminescent EMSA kit
(Thermo Fisher Scientific, York, UK). Reactions included 2.5%
glycerol, 5 mM MgCl2, 50 ng/μL poly(dI
.dC), 0.05% NP40 and 20
fmol labeled probe with or without 200-fold excess of unlabeled
competitor or 2.5 μg nuclear extracts. Complexes were electropho-
resed at 4 °C on 6% DNA retardation gels (Thermo Fisher Scientific,
York, UK) and blotted onto nylon membrane (Roche Diagnostics
Ltd., West Sussex, UK). Label detection used Chemiluminescent
Nucleic Acid Detection Module kit reagents (Thermo Fisher
Scientific, York, UK.
Real-Time Kinetic Growth Assays
Prior to cell seeding in duplicate wells of xCELLigence 96 well
E-plates (ACEA Biosciences, CA), initial medium only reads were
performed in an xCELLigence RTCA Single Plate instrument (ACEA
Biosciences, CA). Plates were removed from the instrument and cells
were seeded at 10,000 per well and allowed to attach for 30 minutes
prior to continuing with the read programme. Twenty-four hours
post-seeding, the run was paused and medium was replaced with
treatment medium. Growth was then monitored every 6 h for 24 h
post-treatment and every 24 h for a further 72 h. Experiments were
performed twice in duplicate.
Statistical Analysis
Statistical analyses were performed in Matlab (Mathworks,
Cambridge, UK).
Results
A Novel Pyrazolopyrimidine Ligand of PGK1 and DJ1
We previously reported development of complementary cell-based
assays focused on regulation of the telomerase gene promoters [17,19]
and cell survival after enforced telomere uncapping [2]. These were
used to probe 1000 and 4500 diverse compounds, respectively. Full
assay methodology and screening results are reported in PubChem
bioassays AID1259240 and AID1259312. Confirmatory assays and
structure activity investigations are also presented in additional
bioassays referred to throughout the text. Characterization of hits inour initial screens in A2780 ovarian cancer cells identified a
pyrazolopyrimidine compound with activity in both assays
(AID1259345 and AID1259347), suggesting a favorable profile as
a potential regulator of immortalisation pathways (CRT0063465,
Figure 2a). To facilitate target identification, structure–activity
relationships (SAR) around the pryrazolopyrimidine scaffold were
probed, leading to development of a tritiated phenylazide derivative
for use as an in-cell photoaffinity cross-linking probe (CRT0105481,
Figure 2a). Several of the derivatives developed during SAR studies
are detailed under PubChem bioassay AID1259345 and summarized
in the methods section. Synthesis data for exemplar compounds are
also given in Supplementary File 1.
To identify targets of the series, A2780 cells were treated with
CRT0105481 at 10 nM or 100 nM for 30 minutes. UV-crosslinking
was performed and proteins harvested for 2D-GE and autoradiography.
Radiolabeled spots excised from the 2D gels were analyzed by LC–MS
to determine their composition. These experiments revealed that
CRT0105481 bound to 2 cellular proteins: glycolytic kinase PGK1 and
multifunctional stress response protein PARK7/DJ1 (Figure S1 in
Supplementary File 2). Commercially available purified recombinant
preparations of these were obtained to confirm binding. Incubation
with CRT0105481 at 10 nM or 100 nM followed by UV crosslinking,
SDS-PAGE and autoradiography demonstrated dose-dependent bind-
ing to both purified targets (Figure S2 in Supplementary File 2).
To investigate binding modes of the unlabeled parent compound
CRT0063465 to these proteins, X-ray crystallography was per-
formed. A PGK1- CRT0063465 co-structure was obtained at 1.9 Å
resolution (Figure 2b). CRT0063465 binds an “open” conformation
of PGK1 equivalent to the ternary complex with 3-phosphoglycerate
and ADP (PDB 2XE7). Data collection and refinement statistics are
presented in Table 1. Binding is perpendicular to the nucleotide
binding site (Figure 2, b and c). The compound bromo-phenyl
moiety occupies the same position as the nucleotide adensosine ring.
The aryl ring is co-planar with the pyrrolopyrimidine scaffold and the
para-substituted bromine engages a deep hydrophobic pocket. The
carboxylate moiety on the distal end of the pryrazolopyrimidine
scaffold is solvent-exposed and does not interact via any polar or
hydrogen bonding interactions with PGK1 (Figure 2, d and e).
CRT0063465 makes no hydrogen-bonding hinge region interac-
tions. This mode would be unusual for an ATP-competitive kinase
inhibitor, which normally bind mainly through this mechanism [28].
To provide further evidence of binding to PGK1, SPR
measurements were performed against immobilized purified PGK1
at a range of CRT0063465 concentrations. Measured Kd was
approximately 24 μM (Figure 2f). It is possible that this relatively
high value results from conformational changes associated with PGK1
immobilization, since CRT0105481 bound PGK1 in vitro and in
cells at nM concentrations. Moreover, in a metabolomics screen
following treatment of HCT116 colorectal cancer cells, which are
known to exhibit a highly glycolytic phenotype [29], with 10 nM
CRT0063465 for 2 h, we observed significant upregulation of a 170
Da species, identified with high confidence as immediate upstream
glycolysis metabolite(s) glyceraldehyde 3-phosphate and/or its isomer
dihydroxyacetone phosphate (Figure S3 and S4, and table S1 in
Supplementary File 2). These results indicate that the compound does
indeed block glycolytic flux in this cell line at nanomolar
concentrations. Several other species were also significantly affected
including uracil, 16-hydroxypalmitate, and various fatty acid
intermediates.
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However, soaking experiments using DJ1 apoform crystals grown as
previously described [30], revealed residual electron density associatedwith DJ1 C106. This residue was found to be in oxidized sulfinic acid
form. In cells, DJ1 C106 oxidation plays a key role in its
cytoprotective function, regulating cellular localization and
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electron density corresponds to the compound carboxylate moiety
(Figure 3, a and b). In this putative structure, the core heterocycle
and aryl ring are disordered and located in the solvent-exposed region.
These could not be refined; therefore, this binding mode cannot be
confirmed.
However, previous studies indicate a role for this residue in diverse
small molecule interactions. Landon and colleagues used the multiple
solvent crystal structures method and computational fragment
mapping to implicate C106 as a ligand-binding hot-spot [33]. The
structure of DJ1 covalently bound to glyoxylate via C106 was also
recently determined [34]. These results support our hypothesis that
this residue represents the binding site for the CRT0063465
carboxylate. This proposed binding mode, involving an electrostatic
interaction, is also consistent with structure–activity data in our cell
based assays indicating that modification of the carboxylate to an
uncharged group causes loss of activity, despite the lack of interaction
of this moiety with PGK1 (Pubchem AID1259345, Figure S5 in
Supplementary File 2, and Figure 2). Taken together our data
indicate that the compound can bind both proteins, although the
mechanism is clearest for PGK1.A PGK1/DJ1 Complex Modulated by CRT0063465
Recently, novel cellular protection roles for DJ1 as a glyoxalase and
deglycating enzyme for both proteins and nucleic acids have been
reported [35–37]. Methylglyoxal, one of the principal cellular
glycating species is produced from glycolytic intermediates dihy-
droxyacetone phosphate and glyceraldehyde-3-phosphate, which are
generated by the aldolase glycolysis reaction upstream of PGK1 [35]
and were increased by CRT0063465 (Figure S3 and S4, and table S1
in Supplementary File 2). Physical interaction between DJ1 and
PGK1 could localize DJ1 close to sites of methylglyoxal production.
Interestingly, a previous proteomic study has also shown association
of DJ1 with several other enzymes of the glycolysis pathway (though
not PGK1) [38]. We therefore investigated the possibility that
CRT0063465 may modulate a PGK1/DJ1 interaction.
We performed co-immunoprecipitations of both proteins in
A2780 ovarian cancer cells, in which the targets were initially
identified (Figure 3c). Cells were treated with vehicle or 10 nM
compound for 1 hour prior to harvesting for immunoprecipitation.
Western blotting of lysates used for immunoprecipitation revealed no
significant change in levels of either protein (left panel). Reciprocal
co-immunoprecipitation confirmed that PGK1 and DJ1 do indeed
interact (middle and right panels). Importantly, these results confirm
the existence of a previously unknown PGK1/DJ1 complex.
Interestingly, CRT0063465 also led to increased pulldown of DJ1
as judged by blotting DJ1 immunoprecipitates with a different DJ1
antibody (middle panel). Correspondingly, co-immunoprecipitatedFigure 2. CRT0063465 binds to phosphoglycerate kinase 1 promotin
and the radiolabeled photoaffinity crosslinking analogue CRT010548
PGK1. Crystal soak-in experiments were performed with CRT0063465
1.9 angstroms. (c), Close-up of CRT0063465 binding mode to PGK1 nu
CRT0063465 promotes a conformational shift in PGK1. The o
to3-phosphoglycerate (yellow, lower lobe) and to either CRT0063465
(yellow compound bound to upper lobe, white ribbon). (e), Close-u
overlaid with ADP structure. (f) Surface Plasmon Resonance dose
immobilized on a GLH sensor chip at either 80 μg/ml or 25 μg/ml and C
was performed using ProteOn Manager software to determine Kd vaPGK1 also increased. However, there was little change in levels of
either protein in the PGK1 pulldowns (right panel). The effect on
DJ1 immunoprecipitation might result from conformation changes
associated with C106 oxidation, perhaps presenting additional
epitopes for the polyclonal pulldown antibody.
To investigate the possible interaction mode of PGK1/DJ1, we
performed in silico docking of both proteins using the
CRT0063465-PGK1 costructure and putative C106-sulfinic
acid-bound DJ1 structure, aligning the proteins along the compound
axis by overlaying the CRT0063465 scaffold from each structure
(Figure 3, d and e). In this model, the DJ1 homodimer (PDB 1SOA)
forms the core, with C106 from each subunit positioned on opposite
faces. CRT0063465 carboxylate interacts with the C106-sulfinic acid
in DJ1 while the bromoaryl ring interacts with the PGK1 nucleotide
b ind ing doma in hyd rophob i c tunne l (F i gu r e 3 d ) .
CRT0063465-bound PGK1 domains are locked in the “open”
conformation, each interacting in a clamp-like fashion with a single
DJ1 monomer on opposite sides of the complex, giving 2:2:2
CRT0063465:DJ1:PGK1 stoichiometry (Figure 3e). Although this is
a computational model, it is in line with the structure activity
relationships observed in our screening assays (Pubchem Bioassay
AID1259345 and Figure S5 in Supplementary File 2). The model is
available at Model Archive (part of Protein Model Portal [39]) with
accession number ma-4hhdq.CRT0063465 Protects Telomeres from Erosion Under Hypo-
glycemia
Recently, several studies have elucidated links between energy
metabolism and telomere signaling. Glucose restriction has been
found to decrease hTERT expression and telomerase activity [14],
while extra-nuclear hTERT has also been reported to influence
glucose uptake by interacting with glucose transporters [15].
CRT0063465 itself is a novel PGK1 nucleotide binding site ligand
that emerged from our screens of telomere signaling. We therefore
investigated whether interactions between telomeres and glycolysis
could be influenced by the compound. For these experiments, we
adopted glucose restriction to further manipulate glycolysis, using
HCT116 colorectal cancer cells, which are known to exhibit a highly
glycolytic phenotype [29]. We have also found CRT0063465 to be
active in our cell-based reporter screening assay in these cells
(PubChem AID1259346). We first performed telomerase activity
(TRAP) assays on cells exposed to hypoglycemia. Our results agree
with those of Wardi and colleagues [14], confirming that glucose
restriction causes dose-dependent reduction in telomerase activity
(Figure 4a).
To determine whether addition of CRT0063465 modifies these
effects in the glucose-restricted setting, we next performed long-term
culturing experiments in the presence of hypoglycemia alone, or ing a conformational shift. (a), molecular structures of CRT0063465
1. (b), Binding modes of CRT0063465 and 3-phosphoglycerate to
at 5 mM concentration and electron density data were collected at
cleotide binding site, overlaid with compound electron density. (d),
verlaid ribbon models show conformations of PGK1 bound
(green compound, brown ribbon) or to ADP in the “closed” form
p of CRT0063465 binding mode to PGK1 nucleotide binding site,
–response curves for CRT0063465 binding to PGK1. PGK1 was
RT0063465 was injected at a range of concentrations. Curve fitting
lue.
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twice-weekly with low-glucose (500 μM) medium with
CRT0036465 maintained on cells throughout. Hypoglycemia
alone led to a relatively stable reduction of telomerase activity over84 days in culture (Figure 4b). Cells could be cultured easily under
long-term hypoglycemia, though growth was substantially reduced
compared to controls supplemented with physiological glucose
(Figure S6 in Supplementary File 2). Treatment with
Figure 4. Blockade of hypoglycemic telomere erosion by CRT0063465. (a), Hypoglycemia suppresses telomerase activity. HCT116 cells
were cultured for 1 week in medium containing different glucose concentrations prior to harvesting for TRAP analysis. Mean ± SEM of 3
experiments performed in triplicate. Least squares curve fitting to the exponential model was performed by using Microsoft Excel Solver.
(b), CRT0063465 does not affect long term telomerase activity suppression by hypoglycemia. HCT116 cells were cultured for 84 days in
medium containing 5 mM (physiological) or 500 μM (hypoglycemic) glucose in the presence of absence of 10 nM or 100 nM
CRT0063465. Samples were taken weekly for TRAP analysis. Mean ± SEM of 3 experiments performed in triplicate. Least squares curve
fitting to linear models was performed using Microsoft Excel Solver. (c), Telomere erosion under hypoglycemia rescued by CRT0063465.
Late time point samples from the long-term culturing experiment in (b) were analyzed for telomere length by Telomere Restriction
Fragment (TRF)-Southern blotting. Experiments were performed twice. A representative blot is shown. (d), Densitometry quantification of
median telomere length. TRF peak signals from both repeats of the long term culturing experiment were analyzed against the lane marker
peaks in GeneTools (Syngene, Cambridge, UK). Mean ± SEM of 2 experiments.
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growth or on total telomerase activity, as judged by the TRAP assay
(Figure 4b).Figure 3. Identification of a complex between PGK1 and DJ1 mo
CRT0063465 and DJ1. (b) Close up of proposed binding mode, sho
residual electron density overlaid with the CRT0063465 carboxylate m
were treated with CRT0063465 or vehicle for 1 h and harvested for imm
detect the presence of each protein in unprecipitated cell lysates
Representative blots are shown. (d), Close-up of candidate interfacial
in DJ1 leaves the PGK1 hydrophobic tunnel accessible to the bromo
proposed 2:2:2 complex between PGK1, DJ1 and CRT0063465. The c
the axis of CRT0063465 by overlaying the compound scaffold in eithWhen telomere restriction fragment Southern blots of the
time-course were examined, consistent with the reduction in
telomerase activity, telomere lengths were decreased in hypoglycemia
relative to physiological conditions. Strikingly, however, despite thedulated by CRT0063465. (a), Putative mode of binding between
wing electron density of the oxidized C106 residue and adjacent
oiety. (c), Detection of a cellular PGK1/DJ1 complex. A2780 cells
unoprecipitation of either target. Immunoblots were performed to
or in immunoprecipitates. The experiment was performed twice.
binding mode. Interaction between CRT0063465 and oxidized C106
aryl portion of CRT0063465. (e), Molecular docking simulation of
ompound-bound PGK1 and DJ1 X-ray structures were aligned along
er structure.
Figure 5. Hypoglycemia and CRT0063465 regulate interaction of PGK1/DJ1 with TRF2 and telomeres. (a), CRT0063465 rescues a nuclear
telomere-binding activity in hypoglycemia. HCT116 cells were cultured for 1 week in 5 mM (physiological) or 500 μM (hypoglycemic)
glucose with or without 10 nM CRT0063465. Post-treatment, nuclear extracts were prepared for gel shift analysis. Mobility of labeled
probe was visualized in the absence of nuclear extract (“probe” lanes), or in the presence of 5 μg nuclear extract from each treatment
condition with (“NucEx + comp” lanes) or without (“NucEx” lanes) presence of excess cold-competitor. The experiment was performed
twice. A representative image is shown. (b), PGK1 and DJ1 binding to TRF2 is modulated by hypoglycemia and CRT0063465. HCT116
cells were cultured for 1 week in 5 mM (physiological) or 500 μM (hypoglycemic) glucose with or without 10 nM CRT0063465.
Co-immunoprecipitation of TRF2 was performed using Dynabeads. Immunoprecipitates were blotted for the presence of DJ1, PGK1,
Ku80 and TRF2. The experiment was performed twice. A representative blot is shown. (c), PGK1 and DJ1 differentially bind to telomeric
DNA under hypoglycemia and CRT0063465 treatment. HCT116 cells were cultured for 1 week in physiological or hypoglycemic
conditions with or without 10 nM CRT0063465 prior to chromatin immunoprecipitation using the antibodies shown. Mean ± SEM of 3
experiments with qPCR performed in triplicate.
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CRT0063465, hypoglycemic erosion of telomeres was blocked in the
presence of the compound at both 100 nM and 10 nM (Figure 4c).
This experiment was performed twice with similar results. Quanti-
fication of both experiments indicated that median telomere length in
hypoglycemic cells reduced by 35% by day 70, relative to
physiological glucose conditions and similar reduction was observed
at days 77 and 84. In 10 nM CRT0063465 treatments, the
maximum reduction observed was only 13% on day 70, and on day
84 lengths were similar to those in the physiological condition (Figure4d). Interestingly, one experiment was continued until day 147.
Analysis of later time points in this experiment suggested that the
effect may be durable over longer periods (Figure S7). Hence,
CRT0063465 appears to block metabolic stress-induced telomere
shortening in the absence of effects on telomerase.
PGK1 and DJ1 Bind TRF2 and are Recruited to Telomeres
Since CRT0063465 blocked hypoglycemic telomere erosion
without affecting telomerase activity, we investigated whether the
mechanism involves direct modulation of telomere signaling. We first
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telomere binding complexes in vitro. HCT116 cells were treated for 1
week in the presence or absence of hypoglycemia and 10 nM
compound. After treatment, nuclear extracts were harvested and
incubated with DIG-labeled telomere sequence probe for gel-shift
analysis. Figure 5a shows formation of a specific complex which was
competed in the presence of excess cold telomere probe. In nuclear
extracts from cells grown under physiological glucose, CRT0063465
had no observable effect on this complex. However, reduced levels
were observed in hypoglycemic nuclear extracts. These results suggest
that hypoglycemia affects a nuclear telomere sequence-directed
DNA-binding activity in vitro. Interestingly, treatment with
CRT0063465 under hypoglycemia restored levels of the complex.
Thus, the telomere length regulation effects observed with
hypoglycemia and CRT0063465 treatment may involve regulation
of telomere binding factors.
We investigated this hypothesis by co-immunoprecipitation and
western blotting of the core shelterin factor TRF2 in HCT116 cells
treated in the presence or absence of hypoglycemia and 10 nM
CRT0063465. Levels of TRF2 were reduced in its own immuno-
precipitates by all treatments (Figure 5b left panels, bottom).
Immunoblotting of the TRF2 immunoprecipitates with PGK1 and
DJ1 confirmed that both proteins also interact with TRF2. PGK1
levels were also reduced in hypoglycemic conditions. However, DJ1
levels were strongly increased, suggesting possible recruitment to the
shelterin complex under hypoglycemia.
We next investigated whether PGK1 and DJ1 proteins are localized
to telomeres by chromatin immunoprecipitation and telomere QPCR
in cells treated in the presence or absence of hypoglycemia and
CRT0063465. Telomeric DNA was detected in the immunoprecip-
itates of both proteins under physiological conditions and without
compound treatment, indicating that they are present at telomeres in
the HCT116 cancer cell line (Figure 5c). Although glycolysis is
generally considered to be cytosolic, nuclear localization of glycolytic
proteins including PGK1 has previously been reported [40,41].
Western blotting confirmed both proteins are present in cytoplasm
and nucleus under all treatment conditions in these cells (Figure S8 in
Supplementary File 2).
Moreover, binding profiles of both proteins at telomeric DNA
were modulated by treatment (Figure 5c). For PGK1, 10 nM
CRT0063465 increased telomere association under physiological
glucose conditions. Interestingly, while hypoglycemia reduced this
association, levels of hypoglycemic telomere PGK1 binding were not
significantly different from controls on treatment with CRT0063465.
Examination of TRF2 telomere association under these treatments
showed a similar profile to PGK1. Levels of telomere-bound TRF2
were substantially reduced under hypoglycemia, but were not
significantly different from physiological controls when hypoglycemic
cells were treated with CRT0063465. For DJ1, compound treatment
did not significantly affect telomere association under physiological
conditions. However, hypoglycemia led to strong recruitment,
ablated by the addition of compound. Hypoglycemic telomere
recruitment may reflect increased binding to TRF2, as detected in the
co-immunoprecipitation experiments (Figure 5b). However, unlike
DJ1-telomere association, the DJ1-TRF2 interaction above was not
ablated by CRT0063465.CRT0063465 Modulates the Composition of ShelterinTogether, these results demonstrate that both PGK1 and DJ1
interact with a core component of shelterin and localize to telomeres.
Further, these associations can be modulated by hypoglycemia and by
CRT0063465. However, severe hypoglycemia is an artificial
condition. To determine whether the compound has other effects
on TRF2 complexes under unstressed conditions, we treated
HCT116 cells grown in physiological glucose with vehicle or 10
nM CRT0063465 and immunoprecipitated TRF2. LC/MS was then
performed to identify other interacting partners in each condition.
Interestingly, in addition to PGK1, multiple other glycolysis
proteins were also detected in the TRF2 complexes. ALDOA, TPI,
GAPDH, ENO1, PKM and LDHA/B were all present in
physiological conditions (Figure 6, a and b), though upstream
components HK, PGI and PFK were not. In effect, the detected
proteins represent two distinct and potentially functional sub-clusters
of the glycolysis cascade, disconnected by the absence of PGAM1
(Figure 6b). Notably, each sub-cluster is potentially ATP-generating.
Quantification of areas under the peaks of each spectrum suggested
most of these were increased in TRF2 complexes by compound
treatment. However, changes were relatively small in most cases.
We also examined the shelterin components present in the TRF2
immunoprecipitates (Figure 6c). In untreated cells, TRF2 itself,
RAP1, and POT1 were detected although TRF1, TPP1 and TIN2
signals were absent from the untreated condition. In the treated
condition, TRF2 levels were slightly decreased as previously observed
in Figure 4. Interestingly, however, signals for TPP1, TIN2 and,
additionally, the 5′-exonuclease Apollo (DCLRE1B) were present
following treatment with CRT0063465. Thus, CRT0063465
treatment appears to modulate the composition of shelterin
complexes in unstressed cells.
Given these effects of the compound, it is of interest to examine
potential protective effects beyond the setting of low glucose, using
alternative treatments that may model telomeropathies. For example,
it was recently shown that small molecule telomerase activator
compound GRN510 suppresses bleomycin-induced lung injury in a
mouse model of idiopathic pulmonary fibrosis [42]. To determine
whether CRT0063465 has similar protective effects against
bleomycin-induced cytotoxicity, we performed kinetic assays using
the xCELLigence platform [43] to monitor real-time growth of
A2780 cells treated with 100 μM bleomycin and 100 nM
CRT0063465 (Figure 6d). We began monitoring growth at 6 h
post-treatment. At 24 h post-treatment the cell index of both
bleomycin/vehicle- and bleomycin/CRT0063465-treated cells in-
creased by approximately 2-fold. At subsequent time-points up to 96
h, cell indices of both treatments decreased. However, a clear
protective effect of CRT0063465 was observed at all later times. At
96 h, the cell index of bleomycin/vehicle-treated cells decreased to
only 0.14, while the index of bleomycin/CRT0063465-treated cells
remained 3.7-fold higher (0.52). Thus, the activity of CRT0063465
in modulating telomere composition independently of telomerase
may have similar effects as telomerase reactivation in protection
against bleomycin-induced toxicity.
Finally, we investigated potential for the compound to protect
against cytotoxic stress due to iron chelation. Desferoxamine (DFO)
is an iron-chelator widely used as a hypoxia mimetic due to its ability
to stabilize HIF1α (leading, among other effects, to increased glucose
uptake and glycolysis) [44]. However, high concentrations/
prolonged treatments result in depletion of cellular iron pools
required for ribonucleotide reductase activity, leading to inhibition
Figure 6. Shelterin modulation and cytoprotection by CRT0063465 in physiological conditions. (a) Identification of multiple glycolysis
pathway proteins in TRF2 complexes under physiological glucose conditions. TRF2 immunoprecipitates obtained after 1 week treatment
of HCT116 cells in 5 mM glucose with or without 10 nM CRT0063465 were analyzed by LC/MS and average total ion counts (TIC) were
obtained for each protein in each condition using Scaffold 4. (b) Schematic representation of TRF2-associated subclusters of the
glycolysis cascade identified in physiological conditions. (c) Identification of shelterin components identified in TRF2 immunoprecipitates
under physiological glucose culture conditions. TRF2 immunoprecipitates were obtained after 1 week treatment in 5 mM glucose with or
without 10 nM CRT0063465 were analyzed by LC/MS and average total ion counts (TIC) were obtained for each protein in each condition
using Scaffold 4. (d), Protection from bleomycin-induced cytotoxicity. A2780 cells were seeded into duplicate wells of xCELLigence 96
well plates and allowed to attach prior to addition of treatments shown. Plate reads were performed every 6 h for 24 h then every 24 h for a
further 72 h. Mean ± SEM of 2 experiments performed in duplicate. (e), Delayed DFO-induced cytotoxicity. A2780 cells were seeded into
duplicate wells of xCELLigence 96 well plates and allowed to attach prior to addition of treatments shown. Plate reads were performed
every 6 h for 24 h then every 24 h for a further 72 h. Mean ± SEM of 2 experiments performed in duplicate.
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We performed xCELLigence experiments over 96 h on A2780 cells
treated with 100 μM DFO and 100 nM CRT0063465 (Figure 6e).
Over 48 h in culture vehicle- or CRT0063465-treated cell indicesincreased to 10.3 and 8.9, respectively. At 72 h, the DFO/
vehicle-treated cell index decreased to 3.4, while that of DFO/
CRT0063465-treated cells continued to increase to 9.6. By 96 h,
both indices dropped substantially. However, the index of
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vehicle-treated cells (1.39 and 0.14, respectively). Therefore, the
compound also substantially delayed cytotoxicity of high dose DFO
treatment.
Discussion
In this study we report the results of complementary cell-based
screens, hit characterization, synthetic routes, and structure–activity
studies leading to a novel pyrazolopyrimidine compound
CRT0063465 and its analogue CRT0105481 that was used to
deconvolute the cellular targets PGK1 and DJ1. We interrogated the
binding mode for both proteins by X-ray crystallography, leading to
the identification of a novel cellular complex between these proteins
and a proposed model for the interaction. We also demonstrate for
the first time that both proteins can bind to TRF2 and associate with
telomeric DNA in vitro and in cells.
The lead compound CRT0063465 is a nucleotide binding site
ligand of PGK1, which increased the concentration of metabolite(s)
identified with high confidence as GAD3P/DHAP in a metabolomics
screen, confirming activity against glycolysis. The compound
modulates telomere length regulation during metabolic stress, an
effect which appears to involve telomere association of PGK1/DJ1
and the critical shelterin factor TRF2. In the absence of metabolic
stress, the compound caused shelterin remodeling, causing recruit-
ment TIN2/TPP1 and the end-processing factor Apollo to TRF2
complexes. The compound also conferred protection against both
bleomycin- and DFO-induced cytotoxicity, which may point to
potential therapeutic uses. Bleomycin-induced lung damage has
previously been used to model idiopathic pulmonary fibrosis [42].
DFO is effective in treatment of iron-overload conditions including
thalassemia and sickle-cell disease, although certain tissues such as
retina are sensitive to its toxic effects [47]. CRT0063465 is active in
cells at low nanomolar concentration and has favorable pharmaco-
kinetics in healthy mice (not shown).
The role of the PGK1/DJ1 complex identified here remains to be
determined, though previous studies have suggested functional
coupling between DJ1 and glycolysis. Interaction with PGK1
would localize DJ1 close to sites of methylglyoxal production,
where its glyoxalase and deglycating activities would be most effective
[35–37]. At the same time, it is plausible that this activity acts as a
sensor of upstream glycolytic intermediate concentrations facilitating
feedback regulation of glycolytic rate. In line with this possibility, DJ1
interacts with Foxo3a in mouse embryonic fibroblasts, resulting in
stimulation of Pink1 transcription and downregulation of HIF1α and
glycolytic flux [48]. In our computational model of the interaction, it
is also sterically unlikely that enzymatic coupling between 1,3-bispho-
sphoglycerate and ADP could take place. Hence, DJ1-bound PGK1
may be catalytically inactive, which may deactivate a key step in the
pathway. Our model is a starting point to guide future mutagenesis
experiments. It will be interesting to determine whether DJ1 mutants
that are defective in PGK1 interaction retain cytoprotective activity.
However, DJ1 interacts with multiple other pathways to mediate
its cytoprotective effects under oxidative stress. These include
upstream regulation of AKT, p38 and JNK signaling under stress
conditions, mediated via interactions with PTEN, ASK1, and
MEKK1 [49]. It is also a known DNA and RNA binding protein
with multiple roles in regulating transcription [50], including
modulation of chromatin and RNA processing factors [51,52].
Furthermore, DJ1 levels are found to be reduced in ATM-null cells[53], suggesting coupling to the DNA damage signaling machinery.
Notably, DJ1 also enhances transcription of hTERT [54]. Therefore,
a role for DJ1 in telomere signaling appears in line with several of
these previously reported functions.
The function of PGK1 at telomeres (and those of the other
glycolys is pathway components we identi f ied in the
TRF2-interactome) is more enigmatic. It has been reported that
shelterin component TIN2 also localizes to mitochondria and
regulates oxidative phosphorylation [55]. In particular, TIN2
knockdown inhibited glycolysis, leading to increased oxygen
consumption and clearly suggesting link between the telosome and
cellular metabolism. The current study is in agreement with Lee et al.,
who previously reported that almost all members of the glycolysis
pathway are capable of physical interaction with one or more
components of shelterin in the setting of a complementation screen
[56]. The glycolytic proteins identified in that study included
phosphofructokinase, aldolase, triosephosphate isomerase,
glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate mu-
tase, enolase, and pyruvate kinase, though not PGK1. We found most
of these in TRF2 immunoprecipitates. Berthelot et al. also previously
identified glyceraldehyde-3-phosphate dehydrogenase as a telomere
associated factor using affinity chromatography based on capture by
telomeric oligonucleotides [57].
Although glycolysis is traditionally considered to be mainly
cytosolic, a number of studies have now demonstrated clearly that
multiple glycolytic proteins including PGK1 also exhibit nuclear
localization [40,41]. Hence, the concept of “moonlighting” glycolytic
proteins [58] has gained traction. Notably, several glycolytic proteins
have also been reported to have specific nuclear functions including
DNA binding activities linked to DNA replication/repair and
resistance to toxic agents [59–61]. PGK1 itself was reported some
years ago to be a primer recognition protein for DNA polymerase-α
with a potential role in lagging-strand synthesis [62]. Since the
glycolytic subclusters we identified here are both potentially
ATP - g en e r a t i n g , a n a t t r a c t i v e h ypo th e s i s i s t h a t
telomere-association allows for locally high ATP levels through direct
recycling of ADP generated during enzymatic remodeling of
telomeres and other potentially ATP-intensive processes such as
DNA damage signaling.
In a genome-wide siRNA screen for senescence regulators, we
recently identified ALDOA as a strong candidate for inhibition to
induce accelerated senescence in cancer cells [18]. Our current results
shed new light on the complexity of coupling between immortality/
senescence and metabolism. We have previously argued that the cell
fate switch between immortalisation and senescence exhibits
distributed control, sensing inputs from multiple cellular processes
[3,17]. Interactions among telomere components and energy
pathways may help explain the known influence of metabolism on
cell aging. It is increasingly clear that multiple non-shelterin factors
participate in telomere homeostasis [4]. Thus, advanced strategies for
manipulating telomere biology either for stability in aging applica-
tions or for instability in cancer therapeutics require both more
detailed understanding of the telosome and highly selective
pharmacological tools.
In summary, from a cell-based screen we have identified a novel
pyrazolopyrimidine chemical series capable of modulating metabolic
stress-induced telomere homeostasis, of altering the composition of
shelterin in unstressed conditions, and which confer protection from
certain cytotoxic stressors. A variety of telomere targeting agents have
906 PGK1 and DJ1 modulate telomere length regulation Bilsland et al. Neoplasia Vol. 21, No. 9, 2019been developed as candidate anti-cancer agents [63], although the
telomere protection literature is more sparse. Recently, however,
encouraging data have emerged for the Geron Corporation's
telomerase activator compound GRN510 [42]. The CRT0063465
mode of action is distinct from previous agents identified in the
telomere protection space, being apparently independent of global
telomerase levels. Our results suggest that the compound may be a
suitable candidate for future interventional studies directed at models
of aging or stress responses, either as a single agent or in combination
to potentially enhance activity of telomerase-activator or other nuclear
remodeling agents such as the recently reported N-acetyltransferase
10 inhibitor Remodelin [64]. In particular, a potentially important
area for future investigation could lie in chemoprevention strategies
focused on telomeropathy syndromes which produce cancer
predisposition.
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